Summary of clinical outcome of all patients who received and tolerated Ikervis treatment, categorised into five indications (total n=387 patients)
| Clinical outcome | DED Total n=285; n (%) | AED Total n=31; n (%) | OMMP/SJS Total n=27; n (%) | Post-graft Total n=14; n (%) | Others Total n=30; n (%) | P value* |
| Resolved/stable | 264 (92.6) | 20 (64.5) | 25 (92.6) | 7 (50.0) | 27 (90.0) | <0.001 |
| Active | 21 (7.4) | 11 (35.5) | 2 (7.4) | 7 (50.0) | 3 (10.0) |
*Comparison was made among the five indications.
AED, allergic eye disease (which included vernal keratoconjunctivitis and atopic keratoconjunctivitis; DED, dry eye disease; OMMP, ocular mucous membrane pemphigoid; SJS, Steven-Johnson syndrome.